Testing effectiveness (Phase 2)Study completedNCT02702388
What this trial is testing
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Who this might be right for
Thyroid Cancer
Eisai Inc. 241